E-resources
Peer reviewed
Open access
-
Gupta, Rohan; Cristea, Mihaela; Frankel, Paul; Ruel, Christopher; Chen, Chen; Wang, Yingyu; Morgan, Robert; Leong, Lucille; Chow, Warren; Koczywas, Marianna; Koehler, Steve; Lim, Dean; Luu, Thehang; Martel, Cynthia; McNamara, Mark; Somlo, George; Twardowski, Przemyslaw; Yen, Yun; Idorenyi, Amanam; Raechelle, Tinsley; Carroll, Mary; Chung, Vincent
Cancer treatment and research communications, 2019, 2019-00-00, 20190101, Volume: 21Journal Article
Oral metronomic chemotherapy, which has low toxicity, has demonstrated promising anti-tumor and anti-angiogenic properties that may lead to prolonged progression-free survival and improved response rates in patients with recurrent epithelial ovarian cancer (EOC). These effects may be enhanced by the co-administration of anti-angiogenic agents. We conducted a randomized phase II clinical trial to evaluate the therapeutic benefit of oral metronomic cyclophosphamide (CTX) alone and with the anti-angiogenic drug celecoxib in patients with gynecological malignancies. 52 patients were randomly assigned to two treatments arms: 50 mg oral CTX daily alone (Arm A) or with 400 mg celecoxib twice daily (Arm B). The primary endpoint was response rate. Secondary endpoints included toxicity, time to treatment failure, and overall survival. In Arm A (n = 26), 3 patients (12%) had stable disease >6 months and 1 (4%) had a partial response. In Arm B, 5 (19%) had stable disease >6 months and 1 patient (4%) had a partial response. There were no significant between-group differences in overall survival (9.69 months 95% CI 3.84–13.18 vs. 12.55 months 6.67–17.61) or in median time to treatment failure (1.84 months 1.68–2.76 vs. 1.92 months 1.64–5.22). The most common adverse events were nausea, vomiting, and abdominal pain. Oral metronomic CTX has activity with no major toxicities in heavily pretreated recurrent gynecological cancers and may be considered in patients with indolent disease. We did not observe any additional benefit of celecoxib treatment, though this may be due to small sample sizes.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.